Scenario: Vittronics Ltd.
Please read this scenario prior to answering the question
Vittronics Ltd. is a leading medical device manufacturer in the highly competitive market for
Migraine Headache Pain Management (MHPM) devices. These tiny wireless devices are implanted in
the brain and can deliver a precise electric shock when the wearable Pain Control Unit (PCU) detects
an increase in stress induced by the onset of a migraine headache.
This technology will be a breakthrough in the treatment of this condition, and several competitors
are striving to be the first to introduce a product into the market. However, all of them must
demonstrate the effectiveness and safety of their products in a set of clinical trials that will satisfy
the regulatory requirements of the countries in the target markets.
The Enterprise Architecture group at Vittronics has been engaged in an architecture development
project to create a Secure Private Immersive Collaborative Environment (SPICE) that will allow
researchers at its product development laboratories worldwide to share information about their
independent clinical trials.
The Vittronics Enterprise Architecture group is a mature organization that has been utilizing TOGAF
for several years. They have recently upgraded to TOGAF 9. The Vittronics Architecture Development
Method (VADM) is strictly based on the TOGAF 9 Architecture Development Method (ADM) with
extensions required to support current good manufacturing practices and good laboratory practices
in their target markets.
The SPICE project team has now completed the Business, Information Systems, and Technology
Architecture phases and has produced a complete set of deliverables for each phase. Due to the
highly sensitive nature of the information that is managed in SPICE, special care was taken to ensure
that each architecture domain included an examination of the security and privacy issues that are
relevant for each domain. A corresponding SPICE Security Architecture has been defined.
The Executive Vice President for Clinical Research is the sponsor of the Enterprise Architecture
activity. He has stated that the changes to the SPICE architecture will need to be rolled out on a
geographic basis that will minimize disruptions to ongoing clinical trials. The work will need to be
done in stages and rolled out in geographical regions.
Refer to the Vittronics Ltd Scenario
You are serving as the Lead Architect for the SPICE project team.
You have been asked to recommend the approach to identify the work packages that will be
included in the Transition Architecture(s).

Based en TOGAF 9, which of the following is the best answer?

A.
Create an Implementation Factor Assessment and Deduction Matrix and a Consolidated Gaps,
Solutions and Dependencies Matrix. For each gap, identify a proposed solution and classify it as new
development, purchased solution, or based on an existing product. Group similar solutions together
to form work packages. Identify dependencies between work packages factoring in the clinical trial
schedules. Regroup the packages into a set of Capability Increments scheduled into a series of
Transition Architectures and documented in an Architecture Definition Increments Table.

B.
Determine the set of Solution Building Blocks required by identifying which Solution Building
Blocks need to be developed and which need to be procured. Eliminate any duplicate building
blocks. Group the remaining Solution Building Blocks together to create the work packages using a
CRLO matrix. Rank the work packages in terms of cost and select the most cost-effective options for
inclusion in a series of Transition Architectures. Schedule the roll out of the work packages to be
sequential across the geographic regions.

C.
Use a Consolidated Gaps, Solutions and Dependencies Matrix as a planning tool. For each gap
classify whether the solution is either a new development, purchased solution, or based on an
existing product. Group the similar solutions together to define the work packages. Regroup the
work packages into a set of Capability Increments to transition to the Target Architecture taking into
account the schedule for clinical trials.

D.
Group the Solution Building Blocks from a Consolidated Gaps, Solutions and Dependencies Matrix
into a set of work packages. Using the matrix as a planning tool, regroup the work packages to
account for dependencies. Sequence the work packages into the Capability Increments needed to
achieve the Target Architecture. Schedule the rollout one region at a time. Document the
progression of the enterprise architecture using an Enterprise Architecture State Evolution table.